Works matching DE "IBRUTINIB"

Results: 45
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.

    Published in:
    Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-02329-y
    By:
    • Landau, Dan A.;
    • Zviran, Asaf;
    • Fein, Joshua;
    • Bozic, Ivana;
    • Rosebrock, Daniel;
    • Cibulskis, Carrie;
    • Livitz, Dimitri;
    • Leshchiner, Ignaty;
    • Getz, Gad;
    • Wu, Catherine J.;
    • Sun, Clare;
    • Herman, Sarah E. M.;
    • Underbayev, Chingiz;
    • Delong Liu;
    • Farooqui, Mohammed Z. H.;
    • Wiestner, Adrian;
    • Sivina, Mariela;
    • Hoellenriege, Julia;
    • Burger, Jan A.;
    • Ravichandran, Sarangan
    Publication type:
    Article
    14
    15
    16
    17

    Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.

    Published in:
    British Journal of Haematology, 2018, v. 183, n. 4, p. 578, doi. 10.1111/bjh.15567
    By:
    • Jain, Preetesh;
    • Kanagal‐Shamanna, Rashmi;
    • Zhang, Shaojun;
    • Ahmed, Makhdum;
    • Ghorab, Ahmad;
    • Zhang, Liang;
    • Ok, Chi Young;
    • Li, Shaoying;
    • Hagemeister, Frederick;
    • Zeng, Dongfeng;
    • Gong, Tiejun;
    • Chen, Wendy;
    • Badillo, Maria;
    • Nomie, Krystle;
    • Fayad, Luis;
    • Medeiros, Leonard J.;
    • Neelapu, Sattva;
    • Fowler, Nathan;
    • Romaguera, Jorge;
    • Champlin, Richard
    Publication type:
    Article
    18

    Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

    Published in:
    British Journal of Haematology, 2018, v. 183, n. 3, p. 421, doi. 10.1111/bjh.15545
    By:
    • Hampel, Paul J.;
    • Larson, Melissa C.;
    • Kabat, Brian;
    • Call, Timothy G.;
    • Ding, Wei;
    • Kenderian, Saad S.;
    • Bowen, Deborah;
    • Boysen, Justin;
    • Schwager, Susan M.;
    • Leis, Jose F.;
    • Chanan‐Khan, Asher A.;
    • Muchtar, Eli;
    • Hanson, Curtis A.;
    • Slager, Susan L.;
    • Kay, Neil E.;
    • Chaffee, Kari G.;
    • Shanafelt, Tait D.;
    • Parikh, Sameer A.
    Publication type:
    Article
    19

    Ibrutinib induces rapid down‐regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia‐related genes in blood and lymph nodes.

    Published in:
    British Journal of Haematology, 2018, v. 183, n. 2, p. 212, doi. 10.1111/bjh.15516
    By:
    • Palma, Marzia;
    • Krstic, Aleksandra;
    • Peña Perez, Lucia;
    • Berglöf, Anna;
    • Meinke, Stephan;
    • Wang, Qing;
    • Blomberg, K. Emelie M.;
    • Kamali‐Moghaddam, Masood;
    • Shen, Qiujin;
    • Jaremko, Georg;
    • Lundin, Jeanette;
    • De Paepe, Ayla;
    • Höglund, Petter;
    • Kimby, Eva;
    • Österborg, Anders;
    • Månsson, Robert;
    • Smith, C. I. Edvard
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 12, p. 2888, doi. 10.1080/10428194.2018.1460474
    By:
    • de Jong, Jan;
    • Hellemans, Peter;
    • De Wilde, Severijn;
    • Patricia, Daniel;
    • Masterson, Tara;
    • Manikhas, Georgii;
    • Myasnikov, Alexander;
    • Osmanov, Dzhelil;
    • Córdoba, Raúl;
    • Panizo, Carlos;
    • de Zwart, Loeckie;
    • Snoeys, Jan;
    • Chauhan, Vijay;
    • Jiao, James;
    • Sukbuntherng, Juthamas;
    • Ouellet, Daniele
    Publication type:
    Article
    34
    35
    36
    37

    Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 11, p. 2588, doi. 10.1080/10428194.2018.1443337
    By:
    • Chari, Ajai;
    • Larson, Sarah;
    • Holkova, Beata;
    • Cornell, Robert F.;
    • Gasparetto, Cristina;
    • Karanes, Chatchada;
    • Matous, Jeffrey V.;
    • Niesvizky, Ruben;
    • Valent, Jason;
    • Lunning, Matthew;
    • Usmani, Saad Z.;
    • Anderson, Larry D.;
    • Chang, Lipo;
    • Lee, Yihua;
    • Pak, Yvonne;
    • Salman, Zeena;
    • Graef, Thorsten;
    • Bilotti, Elizabeth;
    • Chhabra, Saurabh
    Publication type:
    Article
    38
    39
    40
    41
    42
    43

    Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.

    Published in:
    Current Oncology, 2022, v. 29, n. 4, p. 2174, doi. 10.3390/curroncol29040176
    By:
    • Turkes, Fiona;
    • Bryant, Annette;
    • Begum, Ruwaida;
    • Davidson, Michael;
    • Kalaitzaki, Eleftheria;
    • Aresu, Maria;
    • Lazaro-Alcausi, Retchel;
    • Bryant, Jane;
    • Rana, Isma;
    • Chua, Sue;
    • Aronson, Lauren;
    • Hulkki-Wilson, Sanna;
    • Fribbens, Charlotte;
    • Watkins, David;
    • Rao, Sheela;
    • Starling, Naureen;
    • Cunningham, David;
    • Chong, Irene Y.;
    • Chau, Ian
    Publication type:
    Article
    44
    45